Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing.
Leaps by Bayer led a $90 million investment round into Ada, a German digital health startup with an AI-based symptom checker. As part of the deal, the two companies are also striking a broader strategic partnership.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson's and congestive heart failure.
LabTwin's platform can collect data, access information and help manage experiments, streamlining many of the burdensome processes associated with laboratory work.
The funding round was led by Signals Venture Capital and included participation by Talis Capital, Mutschler Ventures, IBB Beteiligungsgesellschaft and Cavalry Ventures.
In previous surveys by Berlin-based Research2Guidance, respondents views on who would be the most important future distributor of apps have shifted quite a bit since 2010.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Eighty-two percent of the app developers surveyed by Research 2 Guidance said they would like to see more apps from health insurance companies, which are projected to become an important distribution channel for healthcare apps.
Mobile health app makers that are successful are more likely to develop apps for hospitals as opposed to people with chronic conditions and tend to rely on revenues from health services delivered through their apps, according to a survey of 5,000 by research2guidance.
65 apps. That’s how many the average big pharma company has created to support their drug portfolios. Pharma’s beyond the pill market has spurred development of a prodigious number of apps. But as Research2markets’ report reveals, there’s a pretty wide gap in the audience these companies are seeking and what they want to achieve with […]